Thomas W Grunt

Using in vitro ovarian cancer models we are investigating mitogenic and anti-apoptotic ErbB/PI3K/AKT/mTOR signaling and lipogenic fatty acid synthase (FASN) pathways. Our studies aim to elucidate the molecular mechanisms of interaction between signaling and metabolic systems and to demonstrate a potential benefit of combined anti-ErbB/PI3K/AKT/mTOR and anti-FASN targeted approaches for the treatment of ovarian cancer.